Drugs being repurposed in hopes they will help against COVID-19 cost relatively little to make but may prove challenging to produce in quantities needed for a pandemic, a drug pricing expert has said.
"Any pharmaceutical company manufacturing any treatment currently in clinical trials against coronavirus needs a clear plan to upscale production massively," said Andrew Hill, a research fellow at the University of Liverpool.
"Otherwise, supplies of these drugs could quickly run out."
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.